Oct 16, 2019 This webinar will explain common differences between FDA and EMA clinical pharmacology expectations to help sponsors better prepare for and achieve global regulatory success.
Certara Introduces Hasharc Decentralized Application for Healthcare at Hedera Hashgraph Open Access Launch
New Certara DApp provides transaction insights on Hedera network and supports data provenance for supply chain uses cases, improving transparency and disclosure for healthcare clients
How Model-Based Meta-Analysis Leverages Public Data to Support Strategic Drug Development Decision Making
Model-based meta-analysis (MBMA) helps sponsors to make the wisest, most informed decisions about the next steps in their drug’s development and market positioning.
This blog described some important strategic considerations for successful development of complex biologics.
Certara Launches Version 8.2 of its Industry-leading Phoenix PK/PD Modeling and Simulation Software for Drug Development
Aligned with newly issued FDA Draft Guidance, Phoenix supports electronic data, methods and results audit, traceability and communication requirements.